To assess the safety of expanded autologous progeny of an adult CD34+ stem cell subset when introduced into the tibial artery and to determine absence of adverse events at the maximum dose of cells of 1,000,000,000 cells in a dose escalation regime.
To assess improvement in bony union as measured by imaging modalities and determine whether there are any significant improvements in early restoration of function as reported by the patients.
17 Years to 75 Years (Child, Adult, Senior)
March 10, 2008
February 22, 2016
Charing Cross Hospital London, United Kingdom
† Study has passed its completion date and status has not been verified in more than two years.